시장보고서
상품코드
234470

항체 관련 제휴 계약 : 계약 조건 및 합의 내용(2015-2022년)

Global Antibody Partnering Terms and Agreements 2015-2022

발행일: | 리서치사: Current Partnering, a division of Wildwood Ventures Limited | 페이지 정보: 영문 1200+ Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

항체(Antibody) 관련 각종 자본 거래/사업 제휴의 계약 체결에 대해 분석했으며, 최근의 각종 계약 체결 동향, 대규모 계약 및 대형 의약품 사업자에 의한 계약 개요, 계약 유형별/임상 단계별/기술별/치료 내용별 계약 리스트 등의 정보를 정리하여 전해드립니다.

주요 요약

제1장 서론

제2장 항체 관련 각종 거래 동향

  • 서론
  • 최근 항체 관련 사업 제휴 건수
  • 가장 활동적인 항체 관련 거래 주체
  • 항체 관련 사업 제휴 : 거래 유형별
  • 항체 관련 사업 제휴 : 치료 분야별
  • 항체 관련 사업 제휴 : 거래 조건
    • 거래 총액
    • 계약금
    • 단계별 기술료
    • 로열티율

제3장 항체 관련 주요 거래

  • 서론
  • 대표적인 자본 거래 - 거래 금액

제4장 항체 관련 가장 활동적인 거래 주체

  • 서론
  • 항체 관련 가장 활동적인 거래 주체
  • 가장 활동적인 거래 주체 : 기업 개요

제5장 항체 관련 계약 체결 리스트

  • 서론
  • 체결된 계약 리스트(디렉토리)

제6장 항체 관련 거래 동향 : 기술 종류별

제7장 항체 관련 자료 센터

  • 항체 관련 온라인 데이터베이스
  • 항체 관련 이벤트/회의
  • 항체 관련 참고문헌

부록

  • 부록(1) - 항체 관련 자본 거래 : 기업별(ABC순)
  • 부록(2) - 항체 관련 자본 거래 : 임상 단계별
    • Drug Discovery
    • 전임상
    • 제I상
    • 제II상
    • 제III상
    • 신청 등록
    • 출시
    • 제형
  • 부록(3) - 항체 관련 자본 거래 : 거래 유형별
    • 자산 구입
    • 권리 양도
    • 대형 의약품 기업의 아웃라이선싱
    • 공동 개발
    • 공동 연구개발(R&D)
    • 공동 마케팅
    • 공동 프로모션
    • CRADA(공동 연구개발 계약)
    • 크로스 라이선싱
    • 개발
    • 유통
    • 주식 구입
    • 평가
    • 양도
    • 합작투자
    • 라이선싱
    • 대출
    • 제조
    • 마케팅
    • 재료 전이
    • 옵션
    • 프로모션
    • 연구
    • 합의
    • 스핀아웃
    • 2차 라이선스
    • 공급
    • 기술 이전
    • 계약 해제
  • 부록(4) - 항체 관련 자본 거래 : 치료 분야별
    • 심혈관
    • 중추신경계
    • 치과
    • 피부과
    • 소화기
    • 혈액
    • 입원 치료
    • 면역
    • 감염증
    • 대사
    • 근골격계 질환
    • 산과
    • 종양(암)
    • 안과
    • 희귀질환
    • 소아과
    • 정신과
    • 호흡기
  • 부록(5) - 자본 거래 유형 : 정의

Wildwood Ventures 소개

KSM 19.12.04

The Global Antibody Partnering Terms and Agreements 2015-2022 report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Antibody Partnering Terms and Agreements 2015 to 2022 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

  • Antibodies
  • Antibody-drug conjugates
  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
  • Polyclonal Antibodies
  • Bispecific antibodies
  • Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
  • This report contains over 2000 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
  • The initial chapters of this report provide an orientation of Antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Antibody dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms.
  • Chapter 3 provides a review of the leading Antibody deals since 2015. Deals are listed by headline value, signed by big pharma, most active Antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 4 provides a comprehensive listing of the top 25 most active companies in Antibody dealmaking with a brief summary followed by a comprehensive listing of Antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
  • Chapter 5 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan 2015. The chapter is organized by specific Antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • In addition, a comprehensive appendix is provided organized by Antibody partnering company A-Z, deal type definitions and Antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • The report also includes numerous tables and figures that illustrate the trends and activities in Antibody partnering and dealmaking since 2015.
  • In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Antibody technologies and products.

Key benefits

Global Antibody Partnering Terms and Agreements 2015 to 2022 provides the reader with the following key benefits:

  • In-depth understanding of Antibody deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual Antibody contracts enter into by the leading 25 bigpharma companies
  • Insight into the terms included in a Antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

  • Global Antibody Partnering Terms and Agreements 2015 to 2022 is intended to provide the reader with an in-depth understanding and access to Antibody trends and structure of deals entered into by leading companies worldwide.

Global Antibody Partnering Terms and Agreements 2015 to 2022 includes:

  • Trends in Antibody dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to over 2000 Antibody online deal records
  • The leading Antibody deals by value since 2015
  • Most active Antibody dealmakers since 2015
  • The leading Antibody partnering resources

In Global Antibody Partnering Terms and Agreements 2015 to 2022, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Antibody Partnering Terms and Agreements 2015 to 2022 report provides comprehensive access to available deals and contract documents for over 2000 Antibody deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise Antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Antibody Partnering 2015-2022 provides the reader with the following key benefits:

  • In-depth understanding of antibody deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 2000 actual antibody deals entered into by the world's biopharma companies, together with contract documents if available
  • Detailed access to actual antibody contracts enter into by the leading companies
  • Identify leading antibody deals by value since 2015
  • Identify the most active antibody dealmakers since 2015
  • Insight into the terms included in a antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

  • 2.1. Introduction
  • 2.2. Antibody partnering over the years
  • 2.3. Most active antibody dealmakers
  • 2.4. Antibody partnering by deal type
  • 2.5. Antibody partnering by therapy area
  • 2.6. Deal terms for antibody partnering
    • 2.6.1 Antibody partnering headline values
    • 2.6.2 Antibody deal upfront payments
    • 2.6.3 Antibody deal milestone payments
    • 2.6.4 Antibody royalty rates

Chapter 3 - Leading antibody deals

  • 3.1. Introduction
  • 3.2. Top antibody deals by value

Chapter 4 - Most active antibody dealmakers

  • 4.1. Introduction
  • 4.2. Most active antibody dealmakers
  • 4.3. Most active antibody partnering company profiles

Chapter 5 - Antibody contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

Appendices

  • Appendix 1 - Antibody deals by company A-Z
  • Appendix 2 - Antibody deals by stage of development
  • Appendix 3 - Antibody deals by deal type
  • Appendix 4 - Antibody deals by therapy area
  • Appendix 5 - Deal type definitions
  • Appendix 6 - Further reading on dealmaking

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Therapeutic antibody definitions
  • Figure 2: Antibody partnering since 2015
  • Figure 3: Active antibody dealmaking activity since 2015
  • Figure 4: Antibody partnering by deal type since 2015
  • Figure 5: Antibody partnering by disease type since 2015
  • Figure 6: Antibody deals with a headline value
  • Figure 7: Antibody deals with an upfront value
  • Figure 8: Antibody deals with a milestone value
  • Figure 9: Antibody deals with a royalty rate value
  • Figure 10: Top antibody deals by value since 2015
  • Figure 11: Most active antibody dealmakers since 2015
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제